Pocket Program - CROI

CROI 2013 Session 34
e Tuesday, 4-6 pm; B406
Session 33–Symposium
HIV Host–Cell Interactions
Conveners:
Chioma Okeoma, Univ of Iowa, Iowa
City, US
Paul Spearman, Emory Univ, Atlanta,
GA, US
107
Interferon-inducible Siglec, CD169, Is the
Mature Dendritic Cell Receptor Essential for
HIV-1 Trans-infection
W Blay Puryear 1 , H Akiyama 1 , S Geer 1 , N Ramirez 1 , X Yu 2 ,
B Reinhard 2 , and Rahm Gummuluru* 1
1 Boston Univ Sch of Med, MA, US and 2 Boston Univ, MA, US
108
TRIM5 Restriction, HIV-1 Uncoating,
and Relationship to Reverse Transcription
Felipe Diaz-Griffero
Albert Einstein Coll of Med, Bronx, NY, US
109
SAMHD1 Restricts HIV-1 Infection in Resting
CD4 + T Cells
Oliver Keppler
Inst of Med Virology, Natl Reference Ctr for Retroviruses,
Univ of Frankfurt, Germany
110
The Antiviral Activities of Tetherin
RP Galao, S Pickering, A Le Tortorec, T Kueck,
and Stuart Neil*
Kings Coll London Sch of Med, Guys Hosp, UK
Objectives: This session is directed to clinicians and scientists
interested in understanding the host cell factors that promote and
restrict HIV-1 replication. It is assumed that participants are familiar
with cell biology, the retroviral lifecycle, and the proteins encoded
in the HIV genome. At the completion of the session, participants
will be knowledgeable about how dendritic cells facilitate HIV
infection through their expression of specific cell-surface proteins,
how host restriction proteins interfere with specific steps during
virus replication, and mechanisms by which the virus has evolved to
escape from these restrictions.
e Tuesday, 4-6 pm; Ballroom 3-4
Session 34–Symposium
Reproductive Hormones and HIV
Conveners:
Ward Cates, FHI360, Research Triangle
Park, NC, US
Nelly Mugo, Univ of Washington,
Nairobi, Kenya
111
Effects of Hormonal Contraceptives that May
Affect Susceptibility to HIV Acquisition in
Women
Christine Mauck
CONRAD, Arlington, VA, US
112
Assessing the Impact of Hormonal
Contraceptives on HIV Risk and
Prevention in Animal Models
Gerardo Garcia-Lerma
CDC, Atlanta, GA, US
113
What Have the Epidemiological Studies
Taught Us about Hormonal Contraceptives
and HIV-related Risks?
Chelsea Polis *1 and R Heffron 2
1 USAID, Office of Population and Reproductive Hlth,
Washington, DC and 2 Univ of Washington, Seattle, US
114
Programmatic Implications: Balancing
Maternal Mortality and HIV Risk
Jennifer Smith* 1 , A Butler 1 , C Polis 2 , S Gregson 1 , D Stanton 2 ,
and T Hallett 1
1 Imperial Coll London, UK and 2 US Agency for Intl Devt,
Washington, DC
5:30-6 pm
Panel Discussion
Objectives: This session is directed to clinicians and scientists
interested in womens health, family planning, and HIV prevention.
This session will be of interest to scientists conducting clinical
studies of HIV prevention and epidemiologists evaluating risk
factors for HIV acquisition and transmission. It is assumed
that participants are familiar with reproductive biology and
the data linking HIV risk with contraceptive hormones. At the
completion of the session, participants will be knowledgeable
about the epidemiologic and biologic data supporting the impact
of reproductive and contraceptive hormones on HIV risk. In
addition, participants will appreciate the public health impact of
effective contraceptives and will learn how modeling studies have
demonstrated that modest increases in HIV risk among women
on hormonal contraceptives are offset by decreases in maternal
mortality associated with unwanted pregnancy.
Program 15
Tuesday
March 5 Oral Sessions